Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Various Michigan Cancer Foundation-7 (MCF7) breast cancer cell lines that overexpress class IIa HDAC9 or that are resistant to the partial antiestrogen 4-hydroxy-tamoxifen (OHTam) were used to study phenotypic changes in response to ER ligands by using transcriptomic and gene set enrichment analyses.
|
31099456 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We successfully apply this workflow in a biological setting and subsequently investigate the differential response to HDAC inhibition in different breast cancer cell lines.
|
31429292 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we reveal a mechanism explaining how HDAC11 plasticity promotes breast cancer growth as well as dissemination from LNs and suggest caution with the use of HDAC inhibitors.
|
31519896 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy.
|
30901675 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate a novel mechanism of HER2-driven carcinogenesis and suggest the applicability of combined HER2 and HDAC targeting in breast cancer therapy.
|
31111958 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of the current study was to characterize the expression of histone deacetylases-3 (HDAC3), a member of class I HDACs, and assess the clinical significance of HDAC3 in breast cancer.
|
29963106 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further study demonstrated WW437 blocked HDACs-EphA2 signaling axis in breast cancer.
|
29759486 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data indicate that LSD1 is a functional alternative subunit of the SIN3A/HDAC complex, providing a molecular basis for the interplay of histone demethylation and deacetylation in chromatin remodelling, and suggest that the LSD1/SIN3A/HDAC complex could be a target for breast cancer therapeutic strategies.
|
29741645 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC inhibitors consists an attractive field for targeted therapy against breast cancer.
|
28011471 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation.
|
26777440 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.
|
27197203 |
2016 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of HDAC9 in MCF7 luminal breast cancer cells led to an increase in cell proliferation and to a decrease in apoptosis.
|
26930713 |
2016 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of breast cancer cells with GTP and EGCG significantly reduced EZH2 and class I HDAC protein levels.
|
24481780 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, cell treatment with both mTOR and HDACs inhibitors shows an additive effect in inhibiting breast cancer proliferation.
|
25801958 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The important role of the MEF2-HDAC axis in ER(+) breast cancer was confirmed in cultured cells.
|
23159930 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HDAC inhibitors have been demonstrated to down-regulate ERα expression in ERα-positive breast cancer cell lines, but the molecular mechanisms are poorly understood.
|
23402757 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this review, the epigenetic-mediated estrogen signaling, controlling both ER level and ER-targeted gene expression in BC, are discussed: (1) ER silencing is frequently observed in BC and is often associated with epigenetic regulations while chemical epigenetic modulators restore ER expression and increase response to treatment;(2) ER-targeted gene expression is tightly regulated by co-recruitment of ER and both coactivators/corepressors including HATs, HDACs, HMTs, Dnmts and Polycomb proteins.
|
23364277 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.
|
23435418 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, although the other HDAC inhibitors, such as SAHA and panobinostat, exhibited activity as potent as entinostat to induce growth inhibition and apoptosis in erbB2-overexpressing breast cancer cells, they had no significant effects on the three miRNAs.
|
23519125 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.
|
23414320 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line.
|
21971930 |
2012 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BRMS1 is a member of mSin3-HDAC transcription co-repressor complex and has been shown to suppress the metastasis of breast cancer and melanoma cells in animal models.
|
17227585 |
2007 |